{"prompt": "['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', '75.', 'McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN', 'expression in paraffin-embedded primary prostate cancer correlates with high Gleason', 'score and advanced stage. Cancer research 1999;59:4291-6.', '76.', 'Yoshimoto M, Cunha IW, Coudry RA, et al. FISH analysis of 107 prostate cancers', 'shows that PTEN genomic deletion is associated with poor clinical outcome. British journal', 'of cancer 2007;97:678-85.', '77.', 'Gurel B, Iwata T, Koh CM, et al. Nuclear MYC protein overexpression is an early', 'alteration in human prostate carcinogenesis. Modern pathology : an official journal of the', 'United States and Canadian Academy of Pathology, Inc 2008;21:1156-67.', '78.', 'Koh CM, Bieberich CJ, Dang CV, Nelson WG, Yegnasubramanian S, De Marzo AM. MYC', 'and Prostate Cancer. Genes & cancer 2010;1:617-28.', '79. Koh CM, Gurel B, Sutcliffe S, et al. Alterations in nucleolar structure and gene', 'expression programs in prostatic neoplasia are driven by the MYC oncogene. The American', 'journal of pathology 2011;178:1824-34.', '80.', 'Gil J, Kerai P, Lleonart M, et al. Immortalization of primary human prostate epithelial', 'cells by c-Myc. Cancer research 2005;65:2179-85.', '81.', 'Bethel CR, Faith D, Li X, et al. Decreased NKX3.1 protein expression in focal prostatic', 'atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason', 'score and chromosome 8p deletion. Cancer research 2006;66:10683-90.', '82.', 'Jenkins RB, Qian J, Lieber MM, Bostwick DG. Detection of c-myc oncogene', 'amplification and chromosomal anomalies in metastatic prostatic carcinoma by', 'fluorescence in situ hybridization. Cancer research 1997;57:524-31.', '83.', 'Sato K, Qian J, Slezak JM, et al. Clinical significance of alterations of chromosome 8 in', 'high-grade, advanced, nonmetastatic prostate carcinoma. Journal of the National Cancer', 'Institute 1999;91:1574-80.', '84.', 'Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS', 'transcription factor genes in prostate cancer. Science (New York, NY) 2005;310:644-8.', '85.', 'Leinonen KA, Saramaki OR, Furusato B, et al. Loss of PTEN is associated with', 'aggressive behavior in ERG-positive prostate cancer. Cancer epidemiology, biomarkers &', 'prevention : a publication of the American Association for Cancer Research, cosponsored', 'by the American Society of Preventive Oncology 2013;22:2333-44.', '86.', 'Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a', 'cell proliferation-associated human nuclear antigen defined by the monoclonal antibody', 'Ki-67. Journal of immunology (Baltimore, Md : 1950) 1984;133:1710-5.', '87.', 'Verhoven B, Yan Y, Ritter M, et al. Ki-67 is an independent predictor of metastasis', 'and cause-specific mortality for prostate cancer patients treated on Radiation Therapy', 'Oncology Group (RTOG) 94-08. International journal of radiation oncology, biology, physics', '2013;86:317-23.', '88.', 'Furusato B, Tan SH, Young D, et al. ERG oncoprotein expression in prostate cancer:', 'clonal progression of ERG-positive tumor cells and potential for ERG-based stratification.', 'Prostate cancer and prostatic diseases 2010;13:228-37.', '89.', 'Chaux A, Albadine R, Toubaji A, et al. Immunohistochemistry for ERG expression as a', 'surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. The American', 'journal of surgical pathology 2011;35:1014-20.', '76', 'Printed on 1/29/2021']['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', '90.', 'van Leenders GJ, Boormans JL, Vissers CJ, et al. Antibody EPR3864 is specific for ERG', 'genomic fusions in prostate cancer: implications for pathological practice. Modern', 'pathology : an official journal of the United States and Canadian Academy of Pathology, Inc', '2011;24:1128-38.', '91.', 'Ross RW, Galsky MD, Scher HI, et al. A whole-blood RNA transcript-based prognostic', 'model in men with castration-resistant prostate cancer: a prospective study. The lancet', 'oncology 2012;13:1105-13.', '92.', 'Simon R. Optimal two-stage designs for phase II clinical trials. Controlled clinical', 'trials 1989;10:1-10.', '93.', 'Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York,', 'NY: John Wiley and Sons; 1980.', '77', 'Printed on 1/29/2021']\n\n###\n\n", "completion": "END"}